Biotech Values

[DewDiligence]

MDCO: If you assume a generic review takes 2 years, the backend post expiration is stretching out.

Unlike P-IV, the FDA does not disclose ANDA’s submitted under P-III, and hence we cannot conclude that there haven’t been any. It’s entirely possible that there are ANDA’s currently in review that will be approved in time for the Angiomax patent expiration in late 2010.